

L3 ANSWER 1 OF 1 MEDLINE
ACCESSION NUMBER: 1998388326 MEDLINE
DOCUMENT NUMBER: 98388326 PubMed ID: 9721431
TITLE: Rapamune (RAPA, rapamycin, sirolimus): mechanism
of action immunosuppressive effect results from blockade
of signal transduction and inhibition of cell cycle
progression.
AUTHOR: Sehgal S N
CORPORATE SOURCE: Wyeth-Ayerst Research, Princeton, New Jersey 08543, USA.
SOURCE: CLINICAL BIOCHEMISTRY, (1998 Jul) 31
(5) 335-40. Ref: 69
Journal code: 0133660. ISSN: 0009-9120.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199811
ENTRY DATE: Entered STN: 19990106
Last Updated on STN: 19990106
Entered Medline: 19981109
AB OBJECTIVE: Rapamune is a novel immunosuppressive agent in Phase III
clinical trial in renal transplantation. Its unique mechanism of action
has created great interest in its use as a biochemical probe of signal
transduction pathways that has provided insight into its molecular
mechanism of action. This article reviews the current state of our
understanding of the mechanism of action of rapamune.